Compare TIC & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIC | ATAI |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | 12760 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | N/A | 2025 |
| Metric | TIC | ATAI |
|---|---|---|
| Price | $8.21 | $5.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $11.20 | ★ $15.88 |
| AVG Volume (30 Days) | 1.8M | ★ 5.6M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | $44.09 | N/A |
| Revenue Next Year | $4.40 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $6.36 | $2.16 |
| 52 Week High | $14.94 | $6.73 |
| Indicator | TIC | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 47.22 | 70.85 |
| Support Level | $7.80 | $4.96 |
| Resistance Level | $9.01 | $5.51 |
| Average True Range (ATR) | 0.39 | 0.33 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 37.57 | 88.36 |
TIC Solutions Inc is a provider of tech-enabled Testing, Inspection, Certification and Compliance (TICC), engineering, and geospatial services. It provides mission-critical services that are essential to the safety, reliability, and efficiency of industrial assets, buildings and public infrastructure. The company's services are often non-discretionary and are driven by regulatory requirements, customer risk management policies, and the need to extend the useful life of critical assets. It operates in North America and serve both public- and private-sector clients. Its public-sector clients include federal, state, and municipal agencies, public utilities, and environmental regulators. Its private-sector clients span industrial, infrastructure, construction, and real estate end markets.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.